Recovery of thalamic damage after decompression by 1H-MRS in combination with Diffusion Tensor Imaging(DTI) in patients with cervical spondylotic myelopathy Authors: Jiangqin Zheng, Yujin Zhang, Baogen Zhao, Ning Wang, Ting Gao, Li Zhang Published: 2026 ABSTRACT BackgroundTo access the changes of thalamic metabolites before and after surgery in patients with Cervical Spondylotic Myelopathy (CSM) using Hydrogen Proton Magnetic Resonance Spectroscopy (1H-MRS) combined with Diffusion Tensor Imaging (DTI) and to investigate its association with improvement in neurological function.MethodsForty-eight CSM patients who underwent cervical decompression surgery from December 2022 to June 2023 were included, and 33 healthy volunteers were recruited. All subjects underwent bilateral thalamic 1H-MRS and DTI scans before the surgical procedure, and subsequently again 6 months later. Neurological function was assessed pre-operatively and post-operatively (6 months) in all patients with CSM using the modified Japanese Orthopaedic Association (mJOA). The changes of mJOA (△mJOA = postoperative mJOA - preoperative mJOA) were employed as an indicator of neurological improvement. The pro- and postoprative N-acetylaspartate/creatine (NAA/Cr), choline/creatine (Cho/Cr), myo-inositol /creatine (mI/Cr), glutamate and glutamine complex/creatine (Glx/Cr) fractional anisotropy (FA), apparent diffusion coefficient (ADC) were statistically compared in CSM patients and healthy controls (HCs). A correlation analysis was conducted to determine the relationship between alterations in pre- and postoperative metabolite ratios (△NAA/Cr, △Cho/Cr, △mI/Cr, △Glx/Cr), △FA, △ADC and ΔmJOA.ResultsResults Compared to the HCs, patients with CSM showed significantly pre- and post-operative NAA/Cr (t = -4.988, P < 0.001; t = -3.562, P = 0.001), Cho/Cr (t = -5.946, P < 0.001; t = -2.764, P = 0.007), mI/Cr (t = -3.988, P < 0.001; t = -2.079, P = 0.041) and FA (t = -4.884, P < 0.001; t = -3.813, P < 0.001). There was no difference in Glx/Cr and ADC between patients in patients with CSM, either preoperatively or postoperatively, compared to HCs. Post-operative NAA/Cr (t = -2.805, P = 0.007), mI/Cr (t = -3.285, P = 0.003) and FA (t = -2.690, P = 0.007) were increased in CSM patients compared to pre-operative NAA/Cr and mI/Cr. In CSM patients, ΔmI/Cr correlated significantly with ΔmJOA (r = 0.4782, P < 0.001).ConclusionThe preliminary findings indicate that metabolites in the thalamus of CSM patients exhibit changes following surgery. Additionally, it has been demonstrated that elevated post operiative mI correlates with improvements in neurological function. Background Cervical spondylotic myelopathy (CSM) represents a prevalent form of degenerative cervical spondylosis. The primary underlying cause of this condition is the compression of the spinal column, which may result from the presence of herniated discs, osteophytes, and other factors [1]. CSM has an insidious onset in the early stages of the disease, manifesting itself as neck pain and stiffness. In the later stages, it progresses to neurological impairments, including motor and sensory dysfunction, as well as paralysis and defecation disorders [2]. Patients with mild-to-moderate CSM are generally treated conservatively. Conversely, early spinal cord decompression surgery is the recommended course of action for advanced severe patients presenting with intractable pain and progressive neurological deterioration. Following surgical decompression of the spinal cord, patients typically demonstrate an initial improvement in motor function and gait, with subsequent, unpredictable improvements in sensory function [3]. A study has demonstrated that patients who have undergone CSM surgery are at an increased risk of progressive deterioration in sensory function in the postoperative period [4]. This indicates that the recovery of motor-sensory function subsequent to surgical intervention cannot be evaluated exclusively on the basis of the degree of injury to the spinal cord component. The presumed reason for this is that impairment of sensory function in patients with CSM cannot be measured solely by the degree of local spinal cord injury. Furthermore, evidence indicates that chronic damage resulting from spinal cord compression can potentially lead to retrograde brain damage [5]. The current body of research confirming retrograde brain damage and functional remodelling in CSM patients has concentrated on the motor centres of the cerebral cortex [6]. This provides a plausible explanation for the neurological remodelling observed in postoperative CSM patients. In a study by List et al. utilising diffusion tensor imaging (DTI) to examine structural alterations of white matter in patients with purely hereditary spastic paraplegia (HSP), it was observed that the fractional anisotropy (FA) values of the internal capsule and corpus callosum were markedly reduced in patients with HSP in comparison to the control group [7]. This finding indicates the potential for retrograde brain damage. Erschbamer et al. also identified alterations in brain metabolites through the utilisation of 1H-MRS in a rat model of experimental spinal cord injury (SCI) [8]. The study conducted by Wang L et al. revealed that CSM results in sensory-motor cortical atrophy; [9] however, the underlying mechanisms responsible for the observed delay in postoperative sensory remodelling remain unclear. The thalamus plays a pivotal role in sensory transduction in the human body, facilitating the projection of sensory impulses to the cerebral cortex. It has been proposed that the thalamus plays a role in the reconstruction and recovery of sensory functions [10]. Neuroimaging studies have revealed an increase in grey matter volume in the thalamus in patients diagnosed with mild hepatic encephalopathy [11]. It has been demonstrated that thalamic metabolic disorders are associated with alterations in regional neural activity and cognitive performance in patients with cirrhosis [12]. Nevertheless, there is a paucity of research examining the alterations in the thalamus and the restoration of sensory function prior to and following decompression surgery in patients with CSM. The objective of this study was to examine the alterations in thalamic in CSM patients prior to and following surgical intervention through the utilisation of hydrogen proton magnetic resonance spectroscopy (1H-MRS) and diffusion tensor imaging(DTI). Additionally, the study aimed to analyse the correlation between these metabolic changes and the improvement of neurological function, with the intention of providing a theoretical foundation for the remodelling of cerebral function in CSM patients following spinal cord injury. Materials and methods Participants A total of 61 patients with CSM were treated between December 2022 and June 2023. To eliminate the potential confounding effects of different dominant cerebral hemispheres, all subjects selected to participate in this study were required to be right-handed. Of these, 54 met the pre-specified inclusion criteria and were invited to participate; 48 ultimately elected to do so (34 males and 14 females, aged 31–70 years, with a mean age of 54.88 ± 10.84 years). The following criteria were used to determine eligibility for inclusion in the study: (a) The magnetic resonance imaging (MRI) scan demonstrated evidence of compression of the cervical spinal cord, including hypertrophy of the ligamentum flavum, cervical spondylosis, and disc herniation. (b) The patient exhibited clinical manifestations of a cervical spinal cord injury. (c) No evidence was found to suggest the presence of amyotrophic lateral sclerosis, an intramedullary tumour, or peripheral neuropathy. (d) No contraindications to MRI examination were identified. (e) The subject had consented to participate in the study of their own volition. The following criteria will result in exclusion from the study: (a) There is no requirement for surgical intervention. (b) A history of depressive, anxiety-related, substance-related, or other psychiatric disorders. (c) A history of psychiatric or neurological disorders among immediate family members. (d) The MRI findings were consistent with the presence of cerebral anomalies, including tumours, haemorrhages, or infarcts. (e) The patient presents with a traumatic injury to the spinal cord. (f) Contraindications to MRI examination were identified. A total of 33 healthy controls were also recruited for the study (18 males and 15 females, aged between 24 and 72 years, with a mean age of 51.79 ± 12.94 years). The study was conducted in accordance with the ethical principles set forth in the Declaration of Helsinki and received approval from the Medical Ethics Committee of the institution. Prior to their participation, written informed consent was obtained from all volunteers and patients. Neurological function evaluation A modified Japanese Orthopaedic Association (mJOA) score was employed to evaluate all subjects’ motor function prior to undergoing magnetic resonance imaging, both preoperatively and at the 6-month postoperative follow-up. The assessment encompassed motor function of the upper and lower extremities, sensory deficits of the extremities and trunk, and bladder function. A maximum score of 18 indicated normal motor function, whereas lower scores indicated more severe dysfunction. The changes of mJOA (△mJOA=postoperative mJOA - preoperative mJOA) was used as an indicator of neurological improvement. MRS acquisition and analysis All subjects underwent preoperative and six-month postoperative 1H-MRS scans in the initial examination on an early morning MRI machine. MRI was conducted using a Philips Ingenia-CX 3.0T MRI system with a 32-channel dedicated head coil. A cranial FSE sequence 3D-T2WI anatomical image scan was initially conducted, employing the following parameters: TR = 2500ms, TE = 248ms, flip angle = 90°, matrix = 252 × 252, FOV = 250 × 250mm2, resolution = 1mmx1mmx1mm, layer thickness = 1 mm, layer spacing = 0 mm, scan time = 4min28s. In accordance with the T2WI anatomical localisation map, a 15 × 15 × 15 mm voxel-sized region of interest was manually positioned in the left thalamus (it is imperative that the cerebrospinal fluid is avoided as much as possible when placing it), and the region of interest in the right thalamus should be symmetrical with the left side when scanning the right thalamus. A single voxel water suppression point-resolved spectroscopy/sequence (PRESS) was employed for the 1H-MRS scanning, with the following parameters: TR = 2000ms, TE = 38ms, NSA = 128, bandwidth = 2000 Hz, and scan time 5min14s. Prior to scanning, both manual and automatic high-order homogenisation were conducted, and automatic water suppression was performed with a water peak half-height linewidth (FWHM) < 15. The regions of interest for the localisation of the thalamus are illustrated in Fig. 1. Fig. 1Localisation of the thalamus. a: axial position; b: sagittal position; c: coronal position Localisation of the thalamus. a: axial position; b: sagittal position; c: coronal position The data obtained from the scan were transferred to a Philips IntelliSpace Portal 9.0 post-processing workstation, where spectral line plotting was performed using the inbuilt spectral analysis software (Spectroview) of the aforementioned workstation. The cranial brain was initially selected as the anatomical location for spectral line fitting. Subsequently, a short TE editing script was selected to run, followed by automatic zero-level (global) and first-level (linear) correction of the spectral phase. Finally, the metabolites for fitting and quantification were selected, with creatine (Cr) used as a reference to obtain the metabolite ratios of the thalamus, namely N-acetylaspartate (NAA)/Cr, choline (Cho)/Cr, myo-inositol (mI)/Cr, and glutamate and glutamine complex (Glx)/Cr. As illustrated in Fig. 2. Fig. 2thalamic metabolite spectra thalamic metabolite spectra DTI acquisition and analysis Diffusion tensor imaging (DTI) of the whole brain was performed in an axial plane by a single-shot spin-echo echo-planar imaging (SS-SE-EPI) sequence: TR = 2741ms, TE = 82ms, flip angle = 90°, FOV = 224 m×224mm2, 20 diffusion encoding directions, b value: 800 s/mm2, layer thickness = 2.5 mm, number of slices = 48, voxel size = 2.5 mm×2.5 mm×2.5 mm, number of signals averaged (NSA) = 2, scan time = 5 min45s. After scanning, the original data of the whole brain DTI were transmitted to the postprocessing workstation of Philips (IntelliSpace Portal 9.0). Fractional anisotraphy (FA), apparent diffusion coefficient (ADC) images was generated automatically after preprocessing (eddy current distortions, head motion correction) using 3d-Neruo application. As illustrated in Fig. 3. For quantitative image analysis, image registration was carried out for each parameter image, and regions of interest (ROIs) were manually defined for each subject inl thalamus in both right and left cerebral hemispheres. The size of each ROIs drawn by a single radiologist with 5 years of experience was 10-15mm2. Fig. 3Thalamic DTI localization map. A: ADC imaging; B: FA imaging Thalamic DTI localization map. A: ADC imaging; B: FA imaging Statistical analyses The analyses were conducted utilising SPSS 26.0 statistical software. The normal distribution of the measures was expressed as the mean ± standard deviation (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{X}$$\end{document}± S). A comparison was made between the demographic and clinical characteristics of CSM patients and HC subjects, employing an independent samples t-test, chi-square analysis and non-parametric tests. A comparative analysis was conducted on thalamic metabolites and DTI values between CSM patients and HC subjects employing an independent samples t-test. A subsequent analysis of the metabolite and DTI values between the preoperative and 6-month postoperative periods in CSM patients was conducted using the paired-samples t test. Pearson’s correlation coefficient was utilised to analyse the differences between the changes in ΔmJOA and the values of thalamic metabolites and DTI changes, respectively. A p-value of less than 0.05 was considered to indicate statistical significance. Results Comparison of demographic and clinical characteristics between CSM patients and Healthy Controls (HCs) The demographic and clinical characteristics of the participants in this study are presented in Table 1. No significant differences were observed between CSM patients and HCs in terms of age, gender, presence of diabetes mellitus, presence of smoking, and BMI. A statistically significant difference was observed between the mJOA scores and the ΔmJOA scores of the CSM patients and the HCs both prior to surgery and at 6 months postoperatively (P < 0.001). Table 1A comparison of the demographic and clinical characteristics of CSM patients and HCsClinical featuresCSM (n = 48)HCs (n = 33)Statistics (X2, t, Z)P-valueAge (years)54.88 ± 10.8451.79 ± 12.94t = 1.1630.248BMI23.96 ± 2.2423.93 ± 2.02t = 0.0470.963Sex (male/female)34/1418/15X2 = 2.2570.133diabetes63X2 = 0.2300.631cigarette smoking2512X2 = 1.9470.163Preoperative mJOA score9.63 ± 2.7917 ± 0Z = -7.897< 0.001*mJOA score at 6 months postoperatively12.56 ± 2.4817 ± 0Z = -7.766< 0.001*ΔmJOA fraction2.94 ± 1.450 ± 0Z = -7.646< 0.001**Indicates statistically significant results. BMI, body mass index Table 1A comparison of the demographic and clinical characteristics of CSM patients and HCsClinical featuresCSM (n = 48)HCs (n = 33)Statistics (X2, t, Z)P-valueAge (years)54.88 ± 10.8451.79 ± 12.94t = 1.1630.248BMI23.96 ± 2.2423.93 ± 2.02t = 0.0470.963Sex (male/female)34/1418/15X2 = 2.2570.133diabetes63X2 = 0.2300.631cigarette smoking2512X2 = 1.9470.163Preoperative mJOA score9.63 ± 2.7917 ± 0Z = -7.897< 0.001*mJOA score at 6 months postoperatively12.56 ± 2.4817 ± 0Z = -7.766< 0.001*ΔmJOA fraction2.94 ± 1.450 ± 0Z = -7.646< 0.001**Indicates statistically significant results. BMI, body mass index A comparison of the demographic and clinical characteristics of CSM patients and HCs *Indicates statistically significant results. BMI, body mass index Comparison of absolute metabolite concentrations and DTI values in CSM patients and HCs The NAA/Cr, Cho/Cr, mI/Cr, Glx/Cr, FA and ADC measured in the left and right thalamus in the CSM patients were not statistically significant at the preoperative and 6-month postoperative time points (Table 2). And those measured in the bilateral thalamus in the HCs were also not statistically significant (Table 3). Accordingly, the mean values in the left and right thalami were employed in both studies. The values of NAA/Cr, Cho/Cr, mI/Cr and FA were found to be significantly lower in the thalamus of CSM patients compared to HCs, both prior to surgery and at 6 months postoperatively (P < 0.05). In contrast, no significant difference was observed in the values of Glx/Cr and ADC in the thalamus of CSM patients compared to HCs (Table 4; Fig. 4). Table 2Comparison of metabolites and DTI values between the left and right sides of the thalamus in the CSM patientsthalamic metabolitesright sideleft sidet-valueP-valuepreoperativeGlx/Cr0.54 ± 0.190.54 ± 0.18-0.0170.987mI/Cr0.67 ± 0.120.67 ± 0.10-0.1990.843Cho/Cr0.68 ± 0.080.67 ± 0.090.5810.563NAA/Cr1.62 ± 0.141.62 ± 0.140.0290.977FA0.24 ± 0.040.24 ± 0.03-0.0960.924ADC0.81 ± 0.060.80 ± 0.05-0.1180.9066 months after surgeryNAA/Cr1.68 ± 0.161.70 ± 0.13-0.3880.699Cho/Cr0.72 ± 0.100.71 ± 0.090.6390.525mI/Cr0.74 ± 0.130.74 ± 0.110.0690.945Glx/Cr0.51 ± 0.180.51 ± 0.170.0810.936FA0.26 ± 0.030.26 ± 0.04-0.2870.774ADC0.79 ± 0.050.79 ± 0.06-0.1400.889 Table 2Comparison of metabolites and DTI values between the left and right sides of the thalamus in the CSM patientsthalamic metabolitesright sideleft sidet-valueP-valuepreoperativeGlx/Cr0.54 ± 0.190.54 ± 0.18-0.0170.987mI/Cr0.67 ± 0.120.67 ± 0.10-0.1990.843Cho/Cr0.68 ± 0.080.67 ± 0.090.5810.563NAA/Cr1.62 ± 0.141.62 ± 0.140.0290.977FA0.24 ± 0.040.24 ± 0.03-0.0960.924ADC0.81 ± 0.060.80 ± 0.05-0.1180.9066 months after surgeryNAA/Cr1.68 ± 0.161.70 ± 0.13-0.3880.699Cho/Cr0.72 ± 0.100.71 ± 0.090.6390.525mI/Cr0.74 ± 0.130.74 ± 0.110.0690.945Glx/Cr0.51 ± 0.180.51 ± 0.170.0810.936FA0.26 ± 0.030.26 ± 0.04-0.2870.774ADC0.79 ± 0.050.79 ± 0.06-0.1400.889 Comparison of metabolites and DTI values between the left and right sides of the thalamus in the CSM patients Table 3Comparison of metabolites and DTI values between the left and right sides of the thalamus in the HCsthalamic metabolitesright sideleft sidet-valueP-valuepreoperativeGlx/Cr0.55 ± 0.200.55 ± 0.12-0.0530.958mI/Cr0.77 ± 0.130.78 ± 0.12-0.1720.864Cho/Cr0.78 ± 0.070.77 ± 0.070.4450.658NAA/Cr1.75 ± 0.161.77 ± 0.14-0.6090.545FA0.27 ± 0.030.28 ± 0.03−0.6420.521ADC0.79 ± 0.040.79 ± 0.04−0.0640.9496 months after surgeryNAA/Cr1.79 ± 0.151.81 ± 0.15−0.5430.589Cho/Cr0.77 ± 0.080.77 ± 0.070.3410.734mI/Cr0.79 ± 0.080.78 ± 0.090.5170.607Glx/Cr0.54 ± 0.210.55 ± 0.18−0.2050.838FA0.28 ± 0.030.28 ± 0.03−0.6140.539ADC0.79 ± 0.040.79 ± 0.05−0.0970.923 Table 3Comparison of metabolites and DTI values between the left and right sides of the thalamus in the HCsthalamic metabolitesright sideleft sidet-valueP-valuepreoperativeGlx/Cr0.55 ± 0.200.55 ± 0.12-0.0530.958mI/Cr0.77 ± 0.130.78 ± 0.12-0.1720.864Cho/Cr0.78 ± 0.070.77 ± 0.070.4450.658NAA/Cr1.75 ± 0.161.77 ± 0.14-0.6090.545FA0.27 ± 0.030.28 ± 0.03−0.6420.521ADC0.79 ± 0.040.79 ± 0.04−0.0640.9496 months after surgeryNAA/Cr1.79 ± 0.151.81 ± 0.15−0.5430.589Cho/Cr0.77 ± 0.080.77 ± 0.070.3410.734mI/Cr0.79 ± 0.080.78 ± 0.090.5170.607Glx/Cr0.54 ± 0.210.55 ± 0.18−0.2050.838FA0.28 ± 0.030.28 ± 0.03−0.6140.539ADC0.79 ± 0.040.79 ± 0.05−0.0970.923 Comparison of metabolites and DTI values between the left and right sides of the thalamus in the HCs Table 4Comparison of metabolites and DTI values between CSM patients and HCsthalamic metabolitesCSMHCst-valueP-valuepreoperativeGlx/Cr0.54 ± 0.180.55 ± 0.16-0.2440.808mI/Cr0.67 ± 0.110.77 ± 0.13-3.988< 0.001*Cho/Cr0.68 ± 0.080.78 ± 0.06-5.946< 0.001*NAA/Cr1.62 ± 0.121.76 ± 0.14-4.988< 0.001*FA0.24 ± 0.030.27 ± 0.02-4.884< 0.001*ADC0.80 ± 0.050.79 ± 0.04-1.0300.3036 months after surgeryNAA/Cr1.69 ± 0.141.80 ± 0.14-3.5620.001*Cho/Cr0.72 ± 0.090.77 ± 0.07-2.7640.007*mI/Cr0.74 ± 0.110.79 ± 0.08-2.0790.041*Glx/Cr0.51 ± 0.170.55 ± 0.19-1.0030.319FA0.26 ± 0.030.28 ± 0.02-3.813< 0.001*ADC0.79 ± 0.040.79 ± 0.04-0.4230.672 Table 4Comparison of metabolites and DTI values between CSM patients and HCsthalamic metabolitesCSMHCst-valueP-valuepreoperativeGlx/Cr0.54 ± 0.180.55 ± 0.16-0.2440.808mI/Cr0.67 ± 0.110.77 ± 0.13-3.988< 0.001*Cho/Cr0.68 ± 0.080.78 ± 0.06-5.946< 0.001*NAA/Cr1.62 ± 0.121.76 ± 0.14-4.988< 0.001*FA0.24 ± 0.030.27 ± 0.02-4.884< 0.001*ADC0.80 ± 0.050.79 ± 0.04-1.0300.3036 months after surgeryNAA/Cr1.69 ± 0.141.80 ± 0.14-3.5620.001*Cho/Cr0.72 ± 0.090.77 ± 0.07-2.7640.007*mI/Cr0.74 ± 0.110.79 ± 0.08-2.0790.041*Glx/Cr0.51 ± 0.170.55 ± 0.19-1.0030.319FA0.26 ± 0.030.28 ± 0.02-3.813< 0.001*ADC0.79 ± 0.040.79 ± 0.04-0.4230.672 Comparison of metabolites and DTI values between CSM patients and HCs *Indicates statistically significant results. Fig. 4Comparison of thalamic metabolites and DTI values between the CSM patients and HCs. A: Comparison of thalamic metabolites and DTI values before surgery; B: Comparison of thalamic metabolites and DTI values 6 months after surgery. Note: *** indicates P < 0.001; ** indicates P < 0.01; * indicates P < 0.05 Comparison of thalamic metabolites and DTI values between the CSM patients and HCs. A: Comparison of thalamic metabolites and DTI values before surgery; B: Comparison of thalamic metabolites and DTI values 6 months after surgery. Note: *** indicates P < 0.001; ** indicates P < 0.01; * indicates P < 0.05 Comparison of thalamic metabolites and DTI values measured at two time points in HCs and CSM patients There were no statistically significant differences in the metabolites and DTI values measured at both time points in the HCs (Table 5). In comparison to the preoperative period, NAA/Cr, mI/Cr and FA value in the thalamus were found to be significantly elevated in the CSM patients 6 months following decompression surgery (P < 0.05). In contrast, Cho/Cr, Glx/Cr and ADC value were not statistically significant, as illustrated in Table 6; Fig. 5. Table 5presents a comparison of metabolites and DTI values between the baseline and the 6-month follow-up in HCsthalamic metabolitesbaseline6-month follow-upt-valueP-valueNAA/Cr1.76 ± 0.141.80 ± 0.14-1.1640.249Cho/Cr0.78 ± 0.060.77 ± 0.070.3520.726mI/Cr0.77 ± 0.130.79 ± 0.08-0.5510.584Glx/Cr0.55 ± 0.160.55 ± 0.190.1120.911FA0.27 ± 0.020.28 ± 0.02-0.9330.351ADC0.79 ± 0.040.79 ± 0.04-0.0880.930 Table 5presents a comparison of metabolites and DTI values between the baseline and the 6-month follow-up in HCsthalamic metabolitesbaseline6-month follow-upt-valueP-valueNAA/Cr1.76 ± 0.141.80 ± 0.14-1.1640.249Cho/Cr0.78 ± 0.060.77 ± 0.070.3520.726mI/Cr0.77 ± 0.130.79 ± 0.08-0.5510.584Glx/Cr0.55 ± 0.160.55 ± 0.190.1120.911FA0.27 ± 0.020.28 ± 0.02-0.9330.351ADC0.79 ± 0.040.79 ± 0.04-0.0880.930 presents a comparison of metabolites and DTI values between the baseline and the 6-month follow-up in HCs Table 6Comparison of metabolites and DTI values between preoperative and 6 months postoperative in the CSM patientsthalamic metabolitespreoperative6 months after surgeryt-valueP-valueNAA/Cr1.62 ± 0.121.69 ± 0.14-2.8050.007*Cho/Cr0.68 ± 0.080.72 ± 0.09-1.9000.064mI/Cr0.67 ± 0.110.74 ± 0.11-3.2850.003*Glx/Cr0.54 ± 0.180.51 ± 0.171.0520.298FA0.24 ± 0.030.26 ± 0.03-2.6900.007*ADC0.80 ± 0.050.79 ± 0.04-1.8480.065*Indicates statistically significant results Table 6Comparison of metabolites and DTI values between preoperative and 6 months postoperative in the CSM patientsthalamic metabolitespreoperative6 months after surgeryt-valueP-valueNAA/Cr1.62 ± 0.121.69 ± 0.14-2.8050.007*Cho/Cr0.68 ± 0.080.72 ± 0.09-1.9000.064mI/Cr0.67 ± 0.110.74 ± 0.11-3.2850.003*Glx/Cr0.54 ± 0.180.51 ± 0.171.0520.298FA0.24 ± 0.030.26 ± 0.03-2.6900.007*ADC0.80 ± 0.050.79 ± 0.04-1.8480.065*Indicates statistically significant results Comparison of metabolites and DTI values between preoperative and 6 months postoperative in the CSM patients *Indicates statistically significant results Fig. 5Comparison of metabolites and DTI values between preoperative and 6-month postoperative periods in the CSM patients. Note: ** indicates P < 0.01 Comparison of metabolites and DTI values between preoperative and 6-month postoperative periods in the CSM patients. Note: ** indicates P < 0.01 Correlation analysis of single voxel changes and DTI changes in thalamic metabolites with ΔmJOA No significant correlation was observed between ΔNAA/Cr, ΔCho/Cr, ΔGlx/Cr, ΔFA and ΔmJOA in CSM patients. Conversely, a significant correlation was identified between ΔmI/Cr, ΔADC and ΔmJOA (P < 0.05), as illustrated in Fig. 6. Fig. 6Correlation plots of each metabolite, DTI valus and ΔmJOA in CSM patients Correlation plots of each metabolite, DTI valus and ΔmJOA in CSM patients Discussion This study represents the investigation of metabolites and DTI values in the thalamus of CSM patients utilising 1H-MRS and DTI technology. The metabolites NAA/Cr, Cho/Cr, mI/Cr and FA values were scanned preoperatively and at the 6-month postoperative follow-up. The results demonstrated a statistically significant decrease in these values in CSM patients compared to healthy controls. Furthermore, a notable elevation in NAA/Cr, mI/Cr and FA values were observed in comparison to the preoperative phase. Furthermore, a correlation was identified between ΔmI/Cr, ΔADC and ΔmJOA in CSM patients during the preoperative and 6-month postoperative follow-up periods. Prior research has demonstrated that CSM not only results in damage to the spinal cord itself, but also gives rise to secondary brain damage. Furthermore, the diminution of sensory components that originate in the distal spinal cord and ascend to the thalamus following injury to the spinal cord results in the disruption of thalamocortical circuits. This may be a contributing factor to the altered clinical functioning observed in patients CSM. A voxel-based morphometric (VBM) analysis conducted by Bernabéu-Sanz Á et al. demonstrated a reduction in grey matter volume in the primary sensorimotor cortex and thalamus in patients with CSM, indicating that CSM may result in brain atrophy [13]. In a study by PENG X et al. of thalamic functional magnetic resonance imaging (fMRI) in patients with CSM, it was demonstrated that thalamic-cortical functional connectivity is altered both preoperatively and postoperatively. This suggests that adaptive alterations may contribute to the maintenance of cortical sensorimotor networks prior to and following spinal cord decompression [10]. In our investigation of the thalamus, we observed a notable decline in thalamic metabolites (NAA/Cr, Cho/Cr, mI/Cr) and FA value prior to surgery and at the 6-month postoperative mark in the CSM patients when compared with the HCs. This finding provides further evidence in support of the proposed hypothesis. NAA is an amino acid that is synthesised in the mitochondria of neurons and is present in both the neurons themselves and their axons. It has been demonstrated that NAA is a neurobiological marker that reflects the structural and functional integrity of neuronal mitochondria [14]. Consequently, NAA levels can be used as an indicator of the integrity of neuronal mitochondria. It can thus be proposed that NAA content is indicative of the functional status of neurons, with a reduction in NAA content suggestive of neuronal damage. The NAA/Cr ratio in the thalamus of CSM patients was found to be significantly lower than that of the HCs, indicating that secondary damage to thalamic neurons may occur following spinal cord damage in CSM patients. The primary location of Cho is within cell membranes [15], and modifications in its composition predominantly reflect metabolic alterations in cell membranes, which are frequently initiated by ischemic diseases. In light of these findings, it can be posited that the observed decline in Cho/Cr is indicative of a reduction in the number of thalamic neuronal cells. The extensive disruption of cell membranes ultimately results in a diminution of the Cho peak. MI is primarily located within glial cells and plays a role in facilitating neuronal connectivity. In a study conducted by Paquette AF et al. on interface organotypic slices prepared in the hippocampus of neonatal mice in culture, an increase in the number of synapses was observed when mI treatment was added to mature brain tissue. In light of these findings, the observed reduction in mI/Cr in the present study may be indicative of a notable decline in thalamic synapses in CSM patients [16]. Glx is a complex of glutamate and glutamine. Glutamate is an excitatory neurotransmitter that participates directly in neurotransmission through the glutamate-glutamine cycle [17]. The absence of alterations in Glx/Cr in CSM patients both pre- and post-operatively indicates that glutamate neurotransmission is not disrupted. DTI is a novel MRI technique that utilises the diffusion direction of water molecules in white matter fibre bundles to visualise the microstructure of these bundles with high sensitivity and specificity. FA and ADC are two common DTI parameters. FA reflects the directionality of water molecules, and its size is related to the integrity of axons and myelin sheaths, as well as the density and parallelism of fibres [18]. ADC has been shown to be a reliable marker of water molecule diffusion in human tissues [19]. It has been established that an increase in the ADC value is indicative of an increase in the water molecule diffusion ability. In the field of CSM, the DTI technique is frequently employed to objectively and quantitatively assess the extent of damage to cervical cord nerve fibres [20, 21]. In this study, it was observed that, in comparison with the HCs group, the FA value of CSM patients was significantly decreased, indicating the destruction of white matter fiber structure in CSM patients. Furthermore, a comparison of the metabolites of the CSM patients preoperatively and 6 months postoperatively revealed a significant increase in NAA/Cr, mI/Cr and FA values, while Cho/Cr and ADC values demonstrated no statistically significant change. The present study demonstrated an increase in NAA/Cr postoperatively, which is inconsistent with the findings of other studies that have examined the preoperative to postoperative changes in NAA/Cr in motor and sensory cortex in patients with CSM, which reported a decrease [3, 22]. The rationale behind this analysis may be that the number of cases is relatively limited, which consequently precludes the ability to account for the more overt compensatory changes. This may indicate that the thalamus, as a crucial node within the cortico-basal ganglia thalamic circuit, plays a pivotal role in the communication between the cortex and subcortical regions. Furthermore, it suggests that neurons within the thalamus are given priority for recovery during neural restoration. MI is primarily located within astrocytes, which are responsible for maintaining the internal and external environment of neuronal cells. Furthermore, astrocytes play a role in the survival, migration, immune modulation, signalling and axonal growth of neurons. An increase in mI/Cr is indicative of an enhancement in the trophic function of neuronal cells, and, in a macroscopic view, a recuperation of thalamic neurological function. It has been put forth that mI is elevated during the initial phases of CSM and subsequently returns to baseline levels over time [23]. The findings of the present study provide support for this hypothesis. The FA values of the thalamus in CSM patients measured post-surgery also increased to a certain extent, which further indicates the restoration of thalamic white matter fibre connections. The Cho/Cr ratio demonstrated no notable alteration between the preoperative and postoperative periods, indicating that the metabolic function of neuronal cell membranes had not yet recovered to a satisfactory extent at the 6-month postoperative mark. The mJOA score is a mainstream modality commonly used to evaluate neurological function in CSM patients, and a decrease in mJOA score reflects the presence of different degrees of neurological dysfunction in CSM patients [24, 25]. The present study employed a comparison of the mJOA scores, which revealed a decline in neurological function in the CSM patients relative to the HCs. The present study yielded a significant positive correlation between thalamic ΔmI/Cr and ΔmJOA in CSM patients, representing a novel finding, to the best of our knowledge. Earlier studies have demonstrated that the level of mI is elevated in the white matter of patients diagnosed with multiple sclerosis [26]. A previous 1H-MRS study demonstrated that the level of mI was elevated in patients with moderate to severe head injury. This increase was attributed to astrocytosis [27, 28]. The precise function of MI in the central nervous system (CNS) remains unclear; however, it is known to be preferentially concentrated in glial cells. One potential function of MI in the CNS is that of an osmotic agent [29]. Moreover, research has demonstrated that mI concentrations in the precentral gyrus are markedly elevated in CSM patients with a relatively brief duration of symptoms (≤ 6 months) [23]. This phenomenon may be attributed to the proliferation of reactive glial cells, which occurs in conjunction with subacute neuroinflammation [30]. It has been demonstrated that glial scarring, which is formed by the overproliferation of astrocytes in the late stages of spinal cord injury, has a significant negative impact on neuronal axonal regeneration [31]. Tsitsopoulos PP et al. demonstrated that the number of astrocytes was elevated in the spinal cord of CSM patients, and established a correlation between this finding and the observed neurological dysfunction [32]. Ibrahim et al. observed the presence of astrocyte proliferation in the vicinity of chronic compression spinal cord injury in rats [33]. Astrocytes play a pivotal role in providing support within the nervous system [34]. The present study demonstrated that the ascending recovery of mI/Cr in CSM patients after surgery was consistent with the pathological manifestations of mI. Furthermore, the correlation between the findings ΔmI/Cr and ΔmJOA indicated that postoperative neurological recovery in CSM patients is reversible. The present study is limited by two factors. The sample size is relatively modest, which may limit the generalisability of the findings. Secondly, the 1H-MRS and DTI examination were conducted manually, which introduces the possibility of discrepancies between the preoperative and postoperative voxels. It is therefore recommended that subsequent studies adopt a more specialised research methodology. Conclusion In conclusion, the 1H-MRS and DTI examination represents a valuable tool for the detection of changes in the levels of relevant metabolites and white matter fiber bundle in the brain following chronic spinal cord injury in CSM patients. It is possible that the thalamic ΔmI/Cr may be associated with the recovery of sensory nerves, which could serve as a potential clinically referable index.